Drug Trial Radar · NCT02327078
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
307
Actual
Start
Nov 26, 2014
Primary completion
Jun 16, 2020
Study completion Jun 16, 2020
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Dec 30, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors and lymphomas. Part 2 will evaluate the safety and tolerability of epacadostat in combination with nivolumab and chemotherapy in subjects with squamous cell carcinoma of head and neck (SCCHN) and non-small cell lung cancer (NSCLC). Phase 2 will include expansion cohorts in 7 tumor types, including melanoma, NSCLC, SCCHN, colorectal cancer, ovarian cancer, glioblastoma and diffuse large B-cell lymphoma (DLBCL).
Conditions
- B-cell Malignancies
- Colorectal Cancer (CRC)
- Head and Neck Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Ovarian Cancer
- Glioblastoma
Interventions
NivolumabDrug
specified dose and dosing schedule
EpacadostatDrug
oral twice daily continuous at the protocol-defined dose
ChemotherapyDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Day 42
- Phase 1, Part 2: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Day 42
- Phase 1, Parts 1 and 2: Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)Time frame: up to approximately 39 months
- Phase 2: Objective Response Rate (ORR) in Participants With Select Solid Tumors Per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 for Participants With Solid Tumors and Per Cheson Criteria for Participants With DLBCLTime frame: From first dose up end of the study (up to approximately 6 years)
- Phase 2: Progression Free Survival (PFS)Time frame: From first dose up end of the study (up to approximately 6 years)
- Phase 2: Overall Survival (OS) Rate of Proportion With GlioblastomaTime frame: Month 9
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
UAB Comprehensive Cancer Center
Birmingham, Alabama
The Angeles Clinic and Research Institute
Los Angeles, California
USC Norris Cancer Center
Los Angeles, California
UCSF - University of California San Francisco
San Francisco, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
The University of Kansas Clinical Research Center
Fairway, Kansas
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Lahey Hospital & Medical Center
Burlington, Massachusetts
NYU Cancer Center
New York, New York
Columbia University, Herbert Irving Comprehensive Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Wake Forest Medical Center Boulevard
Winston-Salem, North Carolina
Sanford Research
Fargo, North Dakota
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Sanford Research
North Sioux City, South Dakota
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Oncology Research
Austin, Texas
MD Anderson Cancer Center
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Huntsman Cancer Institute
Salt Lake City, Utah
Medical College of Wisconsin
Milwaukee, Wisconsin
The Christie NHS Foundation Trust
Manchester, United Kingdom
Oxford University Hospitals NHS Trust
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.